Some embodiments of the disclosure provide new uses of trans-1,3-dilinolein as medicaments and food. In an embodiment, an application of trans-1,3-dilinolein in the preparation of stomachic tonic and an application thereof include the preparation of medicaments for treating gastric cancer. Cell experiments show that trans-1,3-dilinolein promotes the proliferation of human gastric mucosal epithelial cell line GES-1 under normal oxygen and hypoxic conditions and it has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and killing effect on hypoxic gastric cancer cells. At a concentration of 300 μm and more, trans-1,3-dilinolein kills gastric cancer cells significantly and the killing effect becomes more significant under hypoxic conditions.

Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R.sup.1, R.sup.2, R.sup.6 and R.sup.6′ are independently selected from H, (C.sub.1-C.sub.8)alkyl, unsaturated (C.sub.2-C.sub.8)hydrocarbon, and (C.sub.3-C.sub.6)cycloalkyl, being these groups optionally substituted; R.sup.3 is hydrogen or halogen; R.sup.4 is selected from H, (C.sub.1-C.sub.8)alkyl, unsaturated (C.sub.2-C.sub.8)hydrocarbon, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.6-C.sub.12)aryl, and (C.sub.5-C.sub.12)heteroaryl, being these groups optionally substituted; and R.sup.5 is selected from (C.sub.3-C.sub.28)alkyl, unsaturated (C.sub.3-C.sub.28)hydrocarbon, (C.sub.6-C.sub.12)aryl, and (C.sub.5-C.sub.12)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications. ##STR00001##

Transforming growth factor β (TGFβ) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGFβ genes.

Provided herein are combinations of capsaicin and TrpV1 modulators that are useful for treating capsaicin-responsive diseases or disorders.

Provided herein are combinations of capsaicin and TrpV1 modulators that are useful for treating capsaicin-responsive diseases or disorders.

A composition for the treatment of psoriasis, wherein the composition comprises a CB2 receptor binding agent, an immunosuppressive agent an oil; and a healing agent or an anti-inflammatory agent. The CB2 receptor binding agent may be a hemp-derived cannabinoid isolate, a hemp-derived full-spectrum cannabinoid containing extract; a hemp-derived broad-spectrum cannabinoid containing extract, or mixtures thereof

A composition for the treatment of psoriasis, wherein the composition comprises a CB2 receptor binding agent, an immunosuppressive agent an oil; and a healing agent or an anti-inflammatory agent. The CB2 receptor binding agent may be a hemp-derived cannabinoid isolate, a hemp-derived full-spectrum cannabinoid containing extract; a hemp-derived broad-spectrum cannabinoid containing extract, or mixtures thereof

The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.